We selected 2.0 mg aflibercept (Eylea®, Bayer, Leverkusen, Germany) as it is the most commonly used licensed anti-VEGF therapy, with favourable safety and efficacy as a treatment of exudative AMD [9]. Here, VEGFA is linked to age-related macular degeneration.